CSL ( ($AU:CSL) ) has shared an announcement. CSL Limited has announced an update on its ongoing on-market share buy-back program, revealing that ...

CSL ( ($AU:CSL) ) just unveiled an update. CSL Limited announced the cessation of 32,733 securities due to the lapse of conditional rights, as the ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

CSL will invest $2.3 billion to expand its North American manufacturing facilities over the next five years, joining other global pharmaceutical companies seeking exemptions from US President Donald ...

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL is increasing its US manufacturing capacity, joining other pharmaceutical companies in responding to potential future tariffs on imported pharmaceuticals. The company will invest US$1.5 billion in ...

Blood plasma is big business — especially along the U.S.–Mexico border. Every day, thousands of Mexican citizens cross ...

CSL's share price has declined by 35% in 2025, influenced by a challenging US healthcare industry and cautious growth prospects. Despite headwinds, UBS sees potential medium-term recovery, especially ...

Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...